Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

Mirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial in patients with moderate-to-severe ulcerative colitis (UC) (NCT02589665). We explored gene expression changes in colonic tissue fr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical and translational gastroenterology 2023-07, Vol.14 (7), p.e00578-e00578
Hauptverfasser:	Steere, Boyd, Schmitz, Jochen, Powell, Nick, Higgs, Richard, Gottlieb, Klaus, Liu, Yushi, Jia, Bochao, Tuttle, Jay L., Sandborn, William J., Sands, Bruce E., D'Haens, Geert, Reinisch, Walter, Krishnan, Venkatesh
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - adverse effects Colitis, Ulcerative - drug therapy Colitis, Ulcerative - genetics Humans Inflammatory Bowel Disease Tumor Necrosis Factor Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!